Shares of Pfizer rose modestly Tuesday after the drugmaker forecast a drop in revenue and earnings in 2026, driven in part by weaker Covid-19 product sales.Pfizer expects adjusted per-share earnings ...
Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance (5) provided on December 17, 2024. The ...
Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...
Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth ...
Zacks Investment Research on MSN
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong leadership positions in distinct therapeutic areas. NVO is widely recognized ...
The drug company on Tuesday said it launched a strategic review of Pfizer Consumer Healthcare, which sells common over-the-counter products like Advil, Centrum and ChapStick. “A range of options will ...
Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback